Amphotericin B deoxycholate

C. diff Risk


Oral Bioavailability


Approximate Cost


0.3-1.5mg/kg IV daily, infused over several hours. Must be approved by Infectious Disease.

General Information

Common Usage

Fungicidal therapy of yeast/fungus/mold infection, especially of the urinary tract as lipid formulations are otherwise preferred to minimize toxicity

Induction therapy for dimorphic fungii (cocci, blasto, histo)

Drug Monitoring

Renal function, K, Mg, HCO3, liver enzymes, CBC.

Frequency depends on course, but daily reasonable during initiation

Adverse Effects

Infusion related symptoms: fever/rigors/N/V/headache (see additional information)

Electrolyte abnormalities - hypoK and hypoMg, loss of bicarb (see additional information re: electrolyte infusions)

Nephrotoxicity ++

Urinary retention

Major Interactions

Main concern is concomitant nephrotoxins - use should be minimized during amphotericin therapy

Digoxin - increased digoxin toxicity with hypokalemia

Additional Information

Infectious Disease to approve use.

Careful attention to electrolyte and fluid status with boluses (usually 500mL) of NS before and after infusion, as well as K and Mg supplementation PRN


Antimicrobial class: Antifungal - polyene

Pregnancy category: B

Average serum half life: 24.0

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic